An interventional study of ICGL-guided treatment and Conventional Treatment group in Lymphatic Malformation, sponsored by Nanjing Children's Hospital. Completed at 1 site in China. Open to participants aged Up to 14 Years. Per ClinicalTrials.gov, last updated 2025-03-13.
Sponsored by Nanjing Children's Hospital · Not applicable, Interventional, and Treatment
To elucidate the application of indocyanine green (ICG) fluorescence angiography in the treatment of childhood tongue cLM (clinically localized malignancy, presumed context here), providing a clearer scientific basis for subsequent targeted interventions.
42 studies on the registry are indexed under Lymphatic Abnormalities; 17 are open to participants now.
This study's enrollment of 42 is close to the median of 46 across 28 interventional studies indexed under Lymphatic Abnormalities.
Browse Lymphatic Abnormalities studies →Nanjing Children's Hospital is the lead sponsor of 16 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
indocyanine green lymphography guided resection combined with sclerotherapy
Procedure: ICGL-guided treatment
lingual LM with conventional treatment
Procedure: Conventional Treatment group
Indocyanine green lymphography guided resection combined with sclerotherapy
Resection with sclerotherapy
Cured (Reduction in dimension greater than 90%)
Reduction in dimension greater than 90%
Time frame: From enrollment to the end of treatment at 12 weeks
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanjing Children's Hospital